Molnupiravir – Molenzavir 200
Molnupiravir – Molenzavir 200
Presentation
Molenzavir 200 Capsule: Each capsule contains Molnupiravir INN 200 mg.
Pharmacology
Molnupiravir is an investigational antiviral drug, which is the prodrug of the ribonucleoside analog N4-hydroxycytidine. It inhibits the replication of multiple RNA viruses, including SARS-CoV-2. It has broad spectrum antiviral activity against influenza virus and coronavirus- es, such as MERS-CoV, and SARS-CoV. It is aimed at the treatment of COVID-19 in-
- patients hospitalized due to mild, moderate or severe disease,
- non-hospitalized patients with mild or moderate disease.
Indictions
Molnupiravir is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.
| Dose | 800 mg (4 capsules) |
| Dosage frequency | Twice daily |
| Duration | 5 days |
| Route of administration | Oral |
Presentation
Molenzavir 200 Capsule: Each capsule contains Molnupiravir INN 200 mg.
Pharmacology
Molnupiravir is an investigational antiviral drug, which is the prodrug of the ribonucleoside analog N4-hydroxycytidine. It inhibits the replication of multiple RNA viruses, including SARS-CoV-2. It has broad spectrum antiviral activity against influenza virus and coronavirus- es, such as MERS-CoV, and SARS-CoV. It is aimed at the treatment of COVID-19 in-
- patients hospitalized due to mild, moderate or severe disease,
- non-hospitalized patients with mild or moderate disease.
Indictions
Molnupiravir is indicated for treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults with a positive SARS-COV-2 diagnostic test and who have at least one risk factor for developing severe illness.
| Dose | 800 mg (4 capsules) |
| Dosage frequency | Twice daily |
| Duration | 5 days |
| Route of administration | Oral |
